Thu, Aug 21, 2014, 6:22 AM EDT - U.S. Markets open in 3 hrs 8 mins

Recent

% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

arthd_00 8 posts  |  Last Activity: Aug 12, 2014 10:56 AM Member since: Jul 9, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • a "bidding war" would force the shorts to cover and we'd see a $3, $4 + stock.

  • Because this low-life creep Jon Stewart goes way over the line with what he thinks is "comedy." He is cynical, vicious, ill-informed and not funny when he gets on his rants. I have seen such blatant inaccuracies I worry that he will jeopardize the company with his excesses, lies and mean-spirited bashing. It's getting old, very old.

  • Late yesterday there was good news about a European initiation.
    "SARASOTA, Fla., July 31, 2014 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs.

    The Company expects to file a Clinical Trial Application (CTA) by the end of the third quarter with the Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to initiate its clinical trials. Upon CTA approval, a safety and tolerability study will be initiated to investigate escalating doses of Anatabine Citrate. At the same time, Quotient Clinical will employ its RapidFACT(TM) (Rapid Formulation development And Clinical Testing) service to identify the next generation of oral Anatabine Citrate formulations for progression into multiple pivotal Phase 2 proof of concept studies.

    Michael J. Mullan MBBS (MD) PhD, Rock Creek Pharmaceutical's Chairman and CEO, said, "We are excited to be working with the Quotient Clinical team who provide a unique blend of services that integrate formulation development, real time GMP manufacturing and rapid clinical testing. These are exactly the resources and expertise our lead compound needs to expedite the drug development process to prepare us for phase II clinical trials expected to begin in 2015. "

    Mark Egerton, Chief Executive Officer, Quotient Clinical said "Anatabine Citrate represents a potential new and exciting medicine for inflammatory disorders. We are delighted that Rock Creek have selected Quotient Clinical to progress their drug candidate through early development. Our Translational Pharmaceutics platform is proven to reduce program timelines and costs and we look forward to working with Rock Creek to accelerate their development plan".
    ...........................

  • arthd_00 arthd_00 Jul 31, 2014 10:50 AM Flag

    I believe you are right, but maybe not on the share dilution. I think they will use joint ventures and licensing agreements which would throw of a lot of cash which they can and hopefully would use to BUY BACK shares when that day comes.

    Is this a pipe dream? Ask Mullan, ask Chapman, ask Bob Rostkamp, ask a few large institutions who have hung in there a very long time.

  • arthd_00 arthd_00 Jul 18, 2014 2:15 PM Flag

    Wow, the market you are referring to could be HUNDREDS OF BILLIONS OF DOLLARS, and the "deep pocket" guys would fund it.

  • I know a short, he said he's been waiting for today to cover. I asked why and he said, "look this is my last chance to find big sellers (because of the Russell rebalance today) and from here on, I don't want to be short."
    Why? I asked. "Because it's now a new company with a new name, new management, new directors, new direction and they are leaving their baggage behind." He said he didn't know if he'd ever buy the company, "t would depend on technical ("I don't do fundamentals").

    Well I do fundamentals AND I look at "insider motivation" and I asked, why would Drs. Mullan and Chapman be "all in" on Rock Creek. Why would Ted Jenkins leave a successful career to e tying his future to RCP. Why would Rostkamp expand his relationship (knowing what he knows)? And why would "the largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 28,000 employees conducting business in approximately 100 countries, they have helped develop or commercialize all of the top 50 best selling drugs on the market," get involved with RCP? I'm talking about Quintiles and the quote can be found on the new RCP website. Enough Said, THIS IS THE TIME.

  • "Hey look what Paully got away with, first he runs the company down to small gasps, then he demands more money personally for his failures.

  • arthd_00 by arthd_00 May 28, 2014 10:43 AM Flag

    Dear Mr. Perito,
    Someone just sent me the announcement of your severance deal with Star. Are you insane? You know Star doesn’t have that kind of money, in part because of your incompetent management of the company and inability to complete a deal or alliance with anyone on anything. You are suggesting that Star owes you $2.5 million, FOR WHAT? For running the company into the ground? While we shareholders lost 60, 75, 90% of our investment -you sir were being paid. Now that you have destroyed us, you want even more?
    Reconsider this insanity, or meet us in court - loser!

BTX
2.89-0.14(-4.62%)Aug 20 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.